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Abstract: Nonallergic rhinitis (NAR) conditions are currently
considered diagnoses by exclusion. A diagnosis of NAR requires
negative specific IgE responses by skin or serologic testing and
more recently testing to exclude localized production of specific
IgE in the nose. Symptoms are classically aggravated by irritant
triggers such as tobacco smoke, perfumes/fragrances, and tem-
perature or barometric pressure changes. A previously developed
questionnaire survey designed to help physicians recognize dif-
ferences between allergic rhinitis and nonallergic rhinitis sub-
types found that patients with symptom onset later in life (35
years), no family history of allergies, no seasonality or cat-
induced symptoms, and symptoms induced by perfumes and
fragrances had 95% likelihood of having a physician diagnosis
of NAR. Of note, clinical symptoms were not generally useful for
differentiating chronic rhinitis subtypes which has also been
confirmed in a more recent study investigating the relationship
between headaches and chronic rhinitis subtypes (Table 1). In
subsequent studies it was found that a significant percentage of
NAR patients did not experience irritant-induced symptoms,
suggesting that these triggers are not a clinical characteristic that
can be uniformly used for all NAR patients. However, a newly
developed Irritant Index Scale can be used to reliably differen-
tiate pure allergic rhinitis from nonallergic rhinitis with trigger
phenotypes. The use of standardized and validated questionnaires
allows objective characterization of chronic rhinitis subtypes that
appears to improve the accuracy of clinically diagnosing these
patients.
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INTRODUCTION
Nonallergic rhinitis (NAR) conditions are currently con-sidered diagnoses by exclusion. To establish a definitive
diagnosis of vasomotor rhinitis (VMR) and nonallergic rhi-
nitis with eosinophilia syndrome (NARES), all other nonal-
lergic rhinitis syndromes should be properly considered and
excluded.1 A diagnosis of NAR requires negative specific IgE
responses by skin, serologic, or entopy testing. Furthermore,
symptoms are classically aggravated by irritant triggers such
as tobacco smoke, perfumes/fragrances, and temperature or
barometric pressure changes.1 Differentiation of the nonaller-
gic conditions, VMR and NARES, is limited to the presence
or absence of eosinophils in the nasal passages.1 Therefore,
VMR is truly a noninflammatory, nonallergic condition
whereas NARES is an inflammatory, nonallergic condition. It
should be emphasized that symptoms and physical findings
are not pathognomonic for allergic rhinitis (AR) as patients
with NAR often manifest similar features.2,3 Therefore,




An accurate diagnosis of a chronic rhinitis (CR) sub-
type is essential for making correct recommendations for
treatment and preventing complications such as sinusitis and
otitis media.1,2 Previously, we developed a questionnaire
survey designed to help physicians recognize differences
between AR and NAR subtypes.3,4 This study found patients
who developed symptoms later in life (older than 35 years)
and who had no family history of allergies, no seasonal
allergy symptoms or perennial symptoms induced by cats or
other furry pets, and symptoms induced by perfumes and
fragrances had 95% likelihood of having a physician diag-
nosis of NAR.3 Of note, clinical symptoms were not generally
useful for differentiating chronic rhinitis subtypes (Table 1).3
However, this questionnaire was less effective at accurately
identifying patients with an AR phenotype.3
Use of a Rhinitis Questionnaire to Differentiate
Chronic Rhinitis Subtypes
In an attempt to see if this questionnaire would perform
better if administered to a well-characterized seasonal AR
(SAR) population, a modified version of the rhinitis question-
naire was distributed to 136 subjects during visit 1 of a
multicenter mountain cedar SAR study.5 The inclusion crite-
ria for this study were having a history of SAR for 2 or more
years and a positive skin prick test to Texas mountain cedar
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pollen that correlated with symptoms in the past year. Statis-
tical analyses included factor analysis, hypothesis testing, and
univariate regression analyses.5 Informed consent was ob-
tained, and the study met the ethical standards of human
research according to the Helsinki Declaration of 1975 as
revised in 2000.
Not surprising, symptoms were triggered in 85% (116/
136) of patients while outdoors during the spring, summer, or
fall; 45% (61/136) by cats; 29% (39/136) by dogs and; 21%
(29/136) by furry pets. Interestingly, 54% (74/136) of patients
had symptoms triggered by cigarette smoke; 72% (98/136) by
weather changes; 49% (67/136) by perfumes; 35% (47/136)
by incense; and 40% (54/136) by cleaning products. Thus, the
majority of patients enrolled in this SAR study also experi-
enced irritant-induced symptoms in response to perfumes,
cleaning products, incense, and smoke, suggesting that they
also met diagnostic criteria for a nonallergic component to
their chronic rhinitis diagnosis (ie, mixed rhinitis).5 As pre-
viously demonstrated in developing the original question-
naire, factor analysis indicated symptoms to cat, dog, and
other furry pet exposure and perfume, incense, and cleaning
product exposure correlated with the Cronbach  for each
factor being 0.78 and 0.7, respectively (0.7 reliable).3–5
Subsequently, the rhinitis questionnaire was distributed to
subjects in 2 additional AR studies at baseline. Interestingly,
over 88% of enrolled subjects in both studies indicated that they
experienced significant symptoms in response to a spectrum of
irritant triggers (see Tables 3 and 4, unpublished data). There-
fore, the majority of patients enrolled in these SAR studies that
also experienced irritant-induced symptoms in response to per-
fumes, cleaning products, incense, and smoke met diagnostic
criteria for mixed rhinitis (MR).2 These results indicate that the
current criteria used to define the SAR phenotype may be
inadequate. Misclassification of AR patients could explain the
large number of partial or nonresponders to medication in
clinical trials, thereby necessitating enrollment of a larger study
population to demonstrate drug efficacy.
Can Medication Response Differentiate
between Chronic Rhinitis Subtypes?
A subanalysis of the Texas cedar SAR study attempted
to determine if response to previous rhinitis treatments could
be useful as a phenotypic marker for further differentiating
rhinitis subtypes.5 Before study enrollment, 84% of patients
had previously tried oral antihistamines, 67% nasal cortico-
steroid sprays, and 35% intranasal antihistamines (Astelin).
There were no statistically significant differences in
satisfactory rates {[moderate  big effect]/total of treated
patients} between these medications: 76% indicated that oral
antihistamines had a moderate-to-big effect, 85% that nasal
corticosteroids had a moderate-to-big effect, and 83% that
intranasal antihistamines (Astelin) had a moderate-to-big ef-
fect (P  0.2).5 Of interest, patients exhibiting “big effects”
in response to intranasal antihistamines indicated extreme
satisfaction with the medication and were more likely to
manifest symptoms induced by perennial allergens (furry
pets, cats, and dogs) and nonallergic irritant triggers (Table
2).5 These preliminary data warrant further investigation to
determine whether response to medication may be a useful
clinical criterion for distinguishing between CR subtypes.
DEVELOPMENT OF AN IRRITANT INDEX SCALE
INSTRUMENT TO OBJECTIVELY DIFFERENTIATE
BETWEEN ALLERGIC AND NONALLERGIC
RHINITIS SUBTYPES
To address the lack of an objective method for differ-
entiating a pure AR and NAR phenotype, we recently devel-
oped an Irritant Index Scale (Appendix) to be used as an
instrument for classifying CR subtypes. This instrument was
initially administered to 445 patients between ages 17 and 65
years in a large clinical allergy practice, with an allergist’s
diagnosis of CR based on accepted criteria. A physician
diagnosis of AR, which included SAR and perennial AR
(PAR), required that patients had at least 1 positive skin prick
test (SPT) that correlated with their clinical symptoms; a
diagnosis of NAR required that patients had negative SPT
with symptoms in response to odorants/chemical irritants or
weather changes.6 Nasal smears for eosinophilia to differen-
tiate VMR from NARES were obtained. However, because
both groups historically had irritant-induced symptoms, for
TABLE 2. Percentages (No. Positive Responses) of Patients With Symptoms Induced by Allergic and Nonallergic Triggers
That Exhibited a “Big Effect” Indicating Extreme Satisfaction With Their Medication5
Drug Cat Dog Furry Pets Outdoor Weather Changes Tobacco Smoke Perfume Incense Cleaning Agents
Oral AH 52 (15/29) 41 (12/29) 35 (10/29) 69 (20/29) 69 (20/29) 52 (15/29) 45 (13/29) 35 (10/29) 45 (13/29)
Nasal CS 44 (11/25) 28 (7/25) 28 (7/25) 80 (20/25) 56 (14/25) 52 (13/25) 44 (11/25) 40 (10/25) 48 (10/25)
Nasal AH
(Astelin)
83 (5/6) 67 (4/6) 67 (4/6) 83 (5/6) 100 (6/6) 67 (4/6) 83 (5/6) 67 (4/6) 100 (6/6)
AH, H1 antagonists; CS, corticosteroids.
TABLE 1. Prevalence of Symptoms in Patients
Characterized as Allergic Rhinitis and Nonallergic Rhinitis





(n  496) (n  138)
Symptom N (%) N (%) P
Stuffy nose 432 (87) 115 (83) NS
Postnasal drainage 411 (83) 107 (78) NS
Rhinorrhea 396 (80) 79 (57) 0.01
*Allergic rhinitis includes seasonal and perennial allergic rhinitis.
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simplicity, they were all considered NAR. Finally, MR pa-
tients were defined as having features of both AR and
NAR.2,6 All patients at the time of their office visit were
administered the Irritant Index Scale, which asked them to
rate the severity of their upper respiratory symptoms in
response to 21 irritant triggers typically associated with NAR
using a 10-point Likert scale. Triggers included ammonia,
antiperspirants, bleach, cold air, cooking/frying odors, cos-
metics, crude oils, fresh newsprint, hairspray, smog, cleaning
products, mildew odor, paint, perfume, pine odor, soap pow-
der, solvent, varnish, weather changes, tobacco smoke, and
wood smoke. Initially, the total Irritant Index value was
obtained by simply adding each trigger score and calculating
the percentage of the total score (210). The original physician
diagnoses of chronic rhinitis subtypes based on physician
history, physical examination, and skin prick testing to a
panel of aeroallergens was AR in 228 patients, NAR in 119
patients, and MR in 98 patients, respectively. Within this
population, 67% were female and 90% were white. The
median Irritant Index rating based on 21 triggers was 18 for
AR [range 0–166], 23 for MR [range 0–190], and 24 for
NAR [range 0–195]. On the basis of these findings, a cutoff
value24 was chosen to differentiate AR from NAR because
it was felt that the median Irritant Index score for NAR would
adequately differentiate these CR phenotypes.6 With use of
this value, patients were reclassified as follows: AR in 190
patients, NAR in 55 patients, and MR in 128 patients,
respectively. Thus, use of an objective instrument for quan-
tifying irritant-induced symptoms resulted in reclassification
of 41 patients.6 Interestingly, reclassification using this ap-
proach resulted in a prevalence of AR, NAR, and MR, very
FIGURE 1. Rhinitis subtypes: prevalence after reclassification using the Irritant Index score.6,8
TABLE 3. Questionnaire Responses by Patients in a
Seasonal Allergic Rhinitis Trial Investigating MP29–02
MP29–02 Azelastine Fluticasone Placebo
Triggers (N  207) (N  208) (N  207) (N  209)
Temp/weather
changes
143 (69%) 140 (67%) 141 (68%) 141 (68%)
Smoke 134 (65%) 133 (64%) 129 (62%) 131 (63%)
Perfumes/
fragrances
127 (61%) 114 (55%) 111 (54%) 112 (54%)
Incense/ candles 88 (43%) 73 (35%) 77 (37%) 87 (42%)
Cleaning
products
85 (41%) 76 (37%) 77 (37%) 81 (39%)
Any nonallergic
triggers
183 (88%) 184 (89%) 185 (89%) 185 (89%)
TABLE 4. Questionnaire Responses by Patients Enrolled in
a Seasonal Allergic Rhinitis Trial Investigating MP03–33
Azelastine MP03–33 Placebo
Trigger (N  274) (n  285) (n  275)
Temp/weather
changes
198 (72%) 202 (71%) 181 (66%)
Smoke 171 (62%) 175 (61%) 167 (61%)
Perfumes/fragrances 154 (56%) 159 (56%) 144 (52%)
Incense/candles 84 (31%) 106 (37%) 87 (32%)
Household/cleaning
products
107 (39%) 116 (41%) 105 (38%)
Any nonallergic
triggers
240 (88%) 252 (88%) 247 (89%)
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similar to what was previously reported by the National
Rhinitis Classification Task Force (Fig. 1).6–8 It is important
to note that 62 NAR patients were found to have Irritant
Index scores 24, indicating that irritant-induced symptoms
are not a clinical characteristic that can be uniformly used for
all NAR patients.6 However, on the basis of these preliminary
findings, the Irritant Index Scale may allow for a more
accurate classification of AR, NAR, and MR phenotypes
based on currently accepted classical definitions of these
rhinitis subtypes.
More recently, evaluation of the Irritant Index instru-
ment has been expanded to a larger patient population and the
results were reanalyzed to account for possible age and
gender differences.9 The ability to discriminate between rhi-
nitis diagnostic categories, AR and NAR, was investigated
for 153 males (AR  124, NAR  29) and 274 females
(AR  168, NAR  106). Gender differences were observed
in preliminary analyses; therefore, males and females re-
sponding to the Irritant Index Scale have different cut off
values and should be analyzed separately.9 Work is ongoing
to identify specific Irritant Index cut off values that can
accurately differentiate between allergic and nonallergic rhi-
nitis subtypes.
CONCLUSIONS
In summary, the Irritant Index Scale can be used to
clearly differentiate between pure AR and NAR phenotypes.
Patients not meeting criteria for either of these diagnoses
would, by default, be classified as having MR. The subgroup
of NAR patients without irritant-induced triggers requires
further investigation to determine whether these individuals
represent a separate, yet unrecognized, CR phenotype (ie,
NAR without irritant triggers). However, development of
standardized and validated questionnaires and instruments
that objectively characterize chronic rhinitis subtypes appears
to improve the accuracy of clinically diagnosing these pa-
tients. Using these objective criteria to establish pure rhinitis
phenotypes should also improve our ability to investigate the
underlying mechanism(s) of NAR, which will subsequently
lead to more disease-specific treatments for this condition.
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Instructions: Please rate on a scale of 0 to 10 the degree
to which the following irritants cause or aggravate any upper
respiratory symptoms or headaches.
“0” means that the irritant has no effect on creating or
aggravating upper respiratory symptoms or headache, and
“10” means that the irritant has a maximal effect. If it does
not provoke the disease at all, write “0”.
If you avoid the irritant because it aggravates your
symptoms, please rate what your reaction was when you were
exposed to the irritant in the past.
Upper respiratory symptoms may include the follow-
ing: stuffy nose; runny nose; itching of the nose; sneezing;
itchy, red, watery eyes; postnasal drainage.
Irritants Upper Respiratory Symptoms
1. Perfume
2. Hair spray





8. Soap powders (ie, laundry soap)
9. Ammonia (i.e., Lysol, Windex)
10. Household cleaners (ie, Tilex, Comet)
11. Christmas tree odors or Pine-Sol
12. Varnish
13. Solvents (turpentine, alcohol, nail polish remover)
14. Paints
15. Sawdust
16. Crude oil (gasoline, diesel, kerosene)
17. Periods of high air pollution
18. Cold air
19. Weather (rain, dampness, temperature changes)
20. Tobacco smoke/wood smoke (burning logs)
21. Mold/mildew odors
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